Vis enkel innførsel

dc.contributor.authorTobberup, Randi
dc.contributor.authorThoresen, Lene
dc.contributor.authorFalkmer, Ursula
dc.contributor.authorYilmaz, Mette K.
dc.contributor.authorSolheim, Tora Skeidsvoll
dc.contributor.authorBalstad, Trude Rakel
dc.date.accessioned2019-12-09T10:36:26Z
dc.date.available2019-12-09T10:36:26Z
dc.date.created2019-06-22T13:24:16Z
dc.date.issued2019
dc.identifier.citationCritical Reviews in Oncology/Hematology. 2019, 139 96-107.nb_NO
dc.identifier.issn1040-8428
dc.identifier.urihttp://hdl.handle.net/11250/2632267
dc.description.abstractBackground: The aim was to evaluate the effects of current parenteral nutrition (PN) treatment on clinical outcomes in patients with advanced cancer. Methods: This review was conducted according to the PRISMA guidelines (PROSPERO ID: 4201707915). Results: Two underpowered randomized controlled trials and six observational studies were retrieved (n = 894 patients). Health-related quality of life and physical function may improve during anti-neoplastic treatment in who PN treatment is the only feeding opportunity, but not necessarily in patients able to feed enterally. Nutritional status may improve in patients regardless of anti-neoplastic treatment and gastrointestinal function. PN treatment was neither superior to fluid in terminal patients nor to dietary counselling in patients able to feed enterally in regards to survival. The total incidence of adverse events was low. Conclusion: Current PN treatment in patients with advanced cancer is understudied and the level of evidence is weak.nb_NO
dc.language.isoengnb_NO
dc.publisherElseviernb_NO
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.no*
dc.titleEffects of current parenteral nutrition treatment on health-related quality of life, physical function, nutritional status, survival and adverse events exclusively in patients with advanced cancer: A systematic literature reviewnb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionacceptedVersionnb_NO
dc.source.pagenumber96-107nb_NO
dc.source.volume139nb_NO
dc.source.journalCritical Reviews in Oncology/Hematologynb_NO
dc.identifier.doi10.1016/j.critrevonc.2019.04.014
dc.identifier.cristin1707019
dc.description.localcode© 2019. This is the authors’ accepted and refereed manuscript to the article. Locked until 20.04.2020 due to copyright restrictions. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/nb_NO
cristin.unitcode1920,12,0,0
cristin.unitcode194,65,15,0
cristin.unitnameKreftklinikken
cristin.unitnameInstitutt for klinisk og molekylær medisin
cristin.ispublishedtrue
cristin.fulltextpostprint
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal